LSE · ABDX.L
Abingdon Health Plc
£0.09-£0.00 (-3.5%)
Abingdon Health Plc’s quoted price sits in the lower half of its reported 52-week range, 33.19% below the high.
Loading market information…
OTC · CRPOF · USD
Stock price, earnings
Quote as of May 31, 2024, 03:58 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Ceapro Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.39% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Ceapro Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Operating as a biotechnology enterprise, Ceapro Inc. is dedicated to pioneering and bringing to market health and wellness offerings, alongside their underlying technologies, which are all predicated on plant-derived compounds. Its commercial reach extends across the United States, Germany, China, Canada, and various other global markets. The company's operations are divided into two principal sectors. The first, its Active Ingredient Product Technology division, is centered on inventing and employing exclusive extraction methodologies. These are utilized for the manufacturing, refinement, and sale of potent substances like oat beta glucan and avenanthramides, extracted from oats and other sustainable botanical sources, serving both the healthcare and beauty industries. Conversely, the Cosmeceutical Industry segment concentrates on the creation and commercial release of anti-aging goods. These products, formulated from natural active components, are primarily distributed straight to consumers through the company's online portal and via a network of specialized natural product retailers. Established in 1997, Ceapro Inc.'s main corporate office is located in Edmonton, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:26 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£0.09-£0.00 (-3.5%)
Abingdon Health Plc’s quoted price sits in the lower half of its reported 52-week range, 33.19% below the high.
$0.98$0.00 (0.0%)
American Hemp Ventures, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.82% below the high.
$0.82+$0.78 (+2,173.99%)
Titan Medical Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.25% below the high.
$2.11+$0.11 (+5.5%)
Progressive Care, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.11% below the high.
$8.50+$0.50 (+6.25%)
Eiger BioPharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.88% below the high.
$0.03+$0.01 (+24.39%)
Living Cell Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 61.75% below the high.
CA$0.11+CA$0.01 (+10.0%)
Rapid Dose Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 42.11% below the high.
A$0.05A$0.00 (0.0%)
Noxopharm Limited’s quoted price sits in the lower half of its reported 52-week range, 55.45% below the high.
